Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: a post hoc analysis of the EURIDIS and ADONIS trials

ConclusionPatients requiring baseline cardioversion represent a distinct population, having more underlying cardiovascular disease and experiencing shorter time to AF/AFL recurrences. Dronedarone was associated with improved efficacy vs placebo regardless of cardioversion status.This article is protected by copyright. All rights reserved.

Source: Journal of Cardiovascular Electrophysiology - February 22, 2020 Category: Cardiology Authors: Munveer Thind, Harry J. Crijns, Gerald V. Naccarelli, James A. Reiffel, Val érie Corp dit Genti, Mattias Wieloch, Andrew Koren, Peter R. Kowey Tags: ORIGINAL ARTICLE Source Type: research